<DOC>
	<DOCNO>NCT01244646</DOCNO>
	<brief_summary>1 . A prospective , non-interventional study , 125 patient Diabetes Mellitus Type2 enrol , , metformin , sub-optimal glycemic control thus receive additional treatment sulfonylurea ( SU ) derivative . At start 3 6 month , regular visit patient 's General Practitioner , patient complete series questionnaire ( Patient Reported Outcomes , PROs ) direct diabetes general , fear hypoglycemia , body weight , treatment compliance general wellbeing . These PROs worry subscale Hypoglycaemic Fear Survey , Impact Weight Quality Life , revise Diabetes Symptom Checklist , Problem Areas In Diabetes , EuroQol EQ-5D Medication Adherence Report Scale . In total 75 question . The frequency hypoglycemic symptom , incidence hypoglycemic event body weight change assess level adherence treatment investigate . 2 . Diabetic patient , M/F , age &gt; 35 , metformin treat , serum HbA1c â‰¥7.0 % ( within last month ) , informed consent provide , SU therapy add . Patients Type 1 diabetes secondary diabetes exclude , patient unable understand complete questionnaire . 3 . Primary outcome variable outcomes HFS-w IWQOL relation frequency hypoglycemic symptom body weight 6 month weight change 0 6 month . Secondary outcome variable PROs . The frequency hypoglycemic symptom , incidence hypoglycemic event , change body weight level compliance address . 4 . The Intention To Treat analysis use , Last Value Extended Forward 3 6 month case withdrawal 3 month . Changes outcome variable analyse modelling time potential dummy variable Generalized Estimating Equations analysis . 5 . Secondary , outcomes HFS-w IWQOL compare self-reported hypoglycemic symptom , incidence hypoglycemic event , body weight change body weight 0 6 month . Changes PRO 's 0 3 6 month , potential relationship ( change ) different questionnaire , hypoglycemia symptom , weight ( change ) treatment compliance evaluate . A search do baseline characteristic predict outcome change PRO 's , hypoglycemic symptom , hypoglycemic event weight change .</brief_summary>
	<brief_title>Hypoglycemia- Weight-related Quality Life Patients With Diabetes Mellitus Type 2 Sulfonylurea Derivatives .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Diabetes Mellitus Type 2 &gt; 6 month treatment metformin &gt; 4 week HbA1c value &gt; 7.0 therefore sulfonylurea derivative add Able complete series questionnaire Concomitant treatment antidiabetic metformin SU derivative Contraindications use metformin SU derivative Concomitant disease may affect patient 's ability complete study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Type 2</keyword>
	<keyword>DMT2</keyword>
	<keyword>T2DM</keyword>
	<keyword>metformin</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>weight</keyword>
	<keyword>quality life</keyword>
	<keyword>compliance</keyword>
</DOC>